)
Laboratorios Farmaceuticos Rovi (ROVI) investor relations material
Laboratorios Farmaceuticos Rovi Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Operating revenue for the first nine months of 2025 was €525.1 million, down 7% year-over-year, mainly due to a 28% decline in CDMO business, while specialty pharma sales rose 10% to €343.4 million.
Okedi® sales surged 102% to €41.0 million, and the heparin franchise grew 7% to €189.8 million, with enoxaparin sales up 11% to €112.8 million.
Gross margin improved to 67.1% (up 3.5 pp), aided by R&D grants, higher-margin product sales, and lower LMWH raw material prices.
EBITDA fell 11% to €149.5 million, and net profit declined 14% to €97.7 million, reflecting lower revenues and increased R&D expenses.
Strategic milestones included agreements with Roche, Sandoz, and BMS, acquisition of a Phoenix facility, and a €36.3 million R&D grant for the LAISOLID project.
Financial highlights
Specialty pharma business offset CDMO weakness, with Okedi®, Neparvis®, and contrast agents as key growth drivers.
CDMO sales dropped 28% to €181.7 million due to lower Moderna-related revenues and a temporary plant closure for upgrades.
SG&A expenses rose 2% to €177.9 million, and R&D expenses increased 42% to €24.7 million, reflecting clinical trial activity.
Free cash flow more than doubled to €63.3 million, and gross cash position rose to €51.2 million.
Capex increased 14% to €38.5 million, mainly for plant expansions, new filling lines, and ISM® industrialization.
Outlook and guidance
2025 operating revenue expected to decrease by a mid-single-digit percentage versus 2024.
2026 operating revenue projected to grow by a high single-digit to low double-digit percentage, with growth levers including new product launches, CDMO agreements, and AI-powered diagnostics.
Full-year 2025 enoxaparin biosimilar sales expected to rise mid-single-digit; bemiparin sales to increase low single-digit.
Next Laboratorios Farmaceuticos Rovi earnings date
Next Laboratorios Farmaceuticos Rovi earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage